MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma
| Autor: | Ken H. Young, Jianyong Li, Qi Xing Gong, Jin Hua Liang, Li Wang, Lei Fan, Kou Rong Miao, Wei Xu, Zhen Wang, Ting Xun Lu, Jia Zhu Wu, Zhihong Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty BCL2 China DNA Copy Number Variations diffuse large B-cell lymphoma MYC Biology Disease-Free Survival Proto-Oncogene Proteins c-myc Asian People immune system diseases Internal medicine hemic and lymphatic diseases medicine Humans Genetic Predisposition to Disease neoplasms In Situ Hybridization Fluorescence Retrospective Studies Hematology medicine.diagnostic_test Incidence (epidemiology) Incidence Cancer Middle Aged medicine.disease BCL6 Prognosis Immunohistochemistry Lymphoma copy number aberration Proto-Oncogene Proteins c-bcl-2 Multivariate Analysis Cancer research pathology Female Lymphoma Large B-Cell Diffuse Hematopathology Diffuse large B-cell lymphoma Fluorescence in situ hybridization Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Ting-Xun Lu 1 , Lei Fan 1 , Li Wang 1 , Jia-Zhu Wu 1 , Kou-Rong Miao 1 , Jin-Hua Liang 1 , Qi-Xing Gong 2 , Zhen Wang 2 , Ken H. Young 3 , Wei Xu 1 , Zhi-Hong Zhang 2 , Jian-Yong Li 1, 4 1 Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China 2 Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China 3 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China Correspondence to: Jian-Yong Li, e-mail: lijianyonglm@medmail.com.cn Keywords: MYC, BCL2, copy number aberration, diffuse large B-cell lymphoma, pathology Received: February 27, 2015 Accepted: May 18, 2015 Published: May 29, 2015 ABSTRACT Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL). Patients with DLBCL harboring MYC aberrations concurrent with BCL2 or/and BCL6 aberrations constitute a specific group with extremely poor outcome. In this study, we retrospectively investigated the incidence and prognosis of MYC , BCL2 , and BCL6 aberrations with DLBCL patients in Chinese population. We applied fluorescence in situ hybridization and immunohistochemical analysis in 246 DLBCL patients. The results showed that patients with MYC or BCL2 copy number aberration (CNA) had significantly worse overall survival (OS) and progression-free survival (PFS) than negative cases ( P < 0.0001). Patients with both MYC and BCL2 CNA had similar outcomes to those with classic double hit lymphoma or protein double expression lymphoma (MYC and BCL2/BCL6 coexpression). By multivariate analysis, MYC CNA, BCL2 CNA and double CNA were the independent worse prognostic factors. In conclusions, patients with MYC or BCL2 CNA constituted a unique group with extremely poor outcome and may require more aggressive treatment regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|